| Literature DB >> 35582687 |
Nicholas Rolnick1, Ivo Vieira de Sousa Neto2,3, Eduardo Fernandes da Fonseca4, Rodrigo Vanerson Passos Neves4, Thiago Dos Santos Rosa4, Dahan da Cunha Nascimento4.
Abstract
Combining blood flow restriction (BFR) with exercise is considered a relevant, helpful method in load-compromised individuals and a viable replacement for traditional heavy-load strength training. BFR exercise may be particularly useful for those unable to withstand high mechanical stresses on joints resulting in skeletal muscle dysfunction, such as patients with chronic kidney disease (CKD). Current literature suggests that BFR training displays similar positive health benefits to exercise training alone for CKD patients, including maintenance of muscle strength, glomerular filtration rate maintenance, uremic parameters, inflammatory profile, redox status, glucose homeostasis, blood pressure adjustments, and low adverse reports. In this review of nine studies in CKD patients, we clarify the potential safety and health effects of exercise training with BFR compared to exercise training alone and recommend insights for future research and practical use. Furthermore, we introduce relevant gaps in this emerging field, providing substantial guidance, critical discussion, and valuable preliminary conclusions in this demographic of patients. However, based on the limited studies in this area, more research is necessary to determine the optimal BFR exercise programming.Entities:
Keywords: Blood flow restriction; Chronic kidney disease; Inflammation; Renal function; exercise
Year: 2022 PMID: 35582687 PMCID: PMC9081410 DOI: 10.12965/jer.2244082.041
Source DB: PubMed Journal: J Exerc Rehabil ISSN: 2288-176X
Exercise intervention characteristics and outcomes of the studies included in this review
| Study | Type of study | Study groups | Clinical status | Sex (F:M) | Age (yr) | Exercise modality | Exercise protocol | Exercise frequency (day/wk) | Intervention (effects) | Vascular occlusion method | Outcomes | Adverse effects | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute | Chronic | ||||||||||||
|
| RCT | EG+BFR | Stage 4 and 5 CKD; EG+ BFR: 100% HTN, 75% diabetic; EG: 64% HTN, 21.4% diabetic | NR for EG+BFR; 66.7% F, and 71.4% M for EG | 61.33; 60.14 | Physiotherapy | Tennis ball: 6 sets of 10 tennis ball squeezes with 1 min RI with 5 squeezes added each week; Dumbbells: 3 sets of 10 reps of elbow flexion with 1 kg during first 2 weeks, followed by 2 kg for the last 2 weeks of the first month, and 3 kg for the last 4 weeks; Handgrip: 3 sets of 20 contractions with 1 min RI with 40% of the 1-RM | 5 | 8 Weeks | 50% of LOP | ↔ Strength for EG+BFR; ↑ strength for EG; ↑ cephalic vein diameter for EG; ↔ cephalic vein diameter for EG+BFR; ↑ Radial artery diameter for both groups | No | |
|
| CD | EG+BFR | NR, but patients were on HD for more than 3 months | 45.4% M and 63.6% M | 46.6–53.9 | AT | Cycling exercise, 20 min during the first 2 hours of HD with RPE of 12–13 Borg scale (moderate intensity) | - | √ | 50% of LOP | ↑ eKt/V for EG+BFR; ↑ eKt/V for EG; ↑ spKt/V for EG+BFR; ↑ spKt/V for EG; ↓ Urea reduction for EG+BFR; ↓ Urea reduction for EG; ↓ Urea rebound for EG+BFR; ↓ Urea rebound for EG | No | |
|
| RCT | EG+BFR | ESRD; EG+ BFR: 26% diabetic; EG: 39% diabetic | 10 F and 9 M for EG+BFR; 9 F and 11 M for EG | 49.4; 59.8 | AT | Cycling exercise, 20 min for 4 hr during HD; Fist 6 week: 60%–63% of maximal HR and 10–11 of RPE; Following 6 weeks 64%–76% of maximal HR and 12–13 of RPE | 3 Times during HD | 12 Weeks | 50% of LOP | ↔ strength for EG+BFR; ↔ strength for EG; ↑ 6 MWT for EG+BFR; ↔ 6MWT for EG | No | |
|
| CD | EG+BFR | Stage 5 renal disease; 2 patients were diabetic and 4 HTN | 3 F and 7 M | 61 | AT | Cycling exercise, 5 min of warm-up and cool down followed by 10 min bouts of cycling separated by 20 min of RI; Workload for each 10 min bout of 10 W and 30 W equivalent to low-to-moderate RPE | - | √ | 50% of LOP | ↔ Kt/v, and UF between groups; ↔ HR, SBP, DBP and MAP between groups; ↑ RPE for EG+BFR than EG | Yes | |
|
| RCT | EG+BFR | Stage 4 or 5 CKD; EG+ BFR: 100% HTN, 75% diabetic, 50% with CVD; EG: 64% HTN, 21% diabetic, 14% with CVD | NR | 61.33; 60.14 | Physiotherapy | Tennis ball: 6 sets of 10 tennis ball squeezes with 1 min RI with 5 squeezes added each week; Dumbbells: 3 sets of 10 reps of elbow flexion with 1 kg during first 2 weeks, followed by 2 kg for the last 2 weeks of the first month, and 3 kg for the last 4 weeks; Handgrip: 3 sets of 20 contractions with 1 min RI with 40% of the 1-RM. | 5 | 8 Weeks | 50% of LOP | ↔ Strength and arm circumference for EG+BFR; ↔ Strength and arm circumference for EG | Yes | |
|
| RCT | EG+BFR | Stage 2 CKD; Patients in both groups were HTN (100%) | 10 F and 20 M; 12 F and 18 M | 60; 58 | RT | Exercises: bench press, seated row, shoulder press, triceps pulley, barbell curls, leg press 45°, leg extension, and leg curl; first 2 months with 3 sets of 12 reps at 30% of 1-RM; Next 2 months with 3 sets of 10 reps at 40% of 1-RM; Last 2 months, 3 sets of 8 reps at 50% of 1-RM | 3 | 6 Months | 50% of LOP | ↓ Decelerate the decline in eGFR for both groups; ↓ Exercise pressor response for both groups; ↓ Clinic and ambulatory 24 hr blood pressure for both groups; ↓ Vasopressin for both groups; ↑Ang 1–17 for both groups; ↑ NO2-, antioxidant defense, and catalase activity for both groups; ↓ ADMA and F2-isoprostanes for both groups; ↑ Strength for both groups | No | |
|
| RCT | EG+BFR | Stage 2 CKD; Patients in both groups were HTN (100%) and diabetic (100%) | 10 F and 25 M for EG+BFR; 12 F and 23 M for EG | 58; 58 | RT | Exercises: bench press, seated row, shoulder press, triceps pulley, barbell curls, leg press 45°, leg extension, and leg curl; first 2 months with 1–3 sets of 12 reps at 30% of 1-RM; Next 2 months with 2–3 sets of 10 reps at 40% of 1-RM; Last 2 months, 3 sets of 8 reps at 50% of 1-RM | 3 | 6 Months | 50% of LOP | ↓ Decelerate the decline in eGFR for both groups; ↔ Creatinine concentrations for both groups; ↑ Klotho-FGF23 for both groups; ↓TNF-α for both groups; ↑ IL-10 and IL-15 for both groups; ↓ IL-18 for both groups; ↑ Strength for both groups | NR | |
|
| RCT | EG+BFR | Stage 2 CKD | NR | 58.06; 58.09 | RT | Exercises: bench press, seated row, shoulder press, triceps pulley, barbell curls, leg press 45°, leg extension, and leg curl; first 2 months with 1–3 sets of 12 reps at 30% of 1-RM; Next 2 months with 2–3 sets of 10 reps at 40% of 1-RM; Last 2 months, 3 sets of 8 reps at 50% of 1-RM | 3 | 6 Months | 50% of LOP | ↓ Decelerate the decline in eGFR for both groups; ↓ Δ values of MPO for both groups; ↑ Δ values of PON1 for both groups; ↑ Δ values of RR and SDNN; ↑ Δ values of RMSSD for EG+BFR; ↑ Δ values of VLF for EG | NR | |
|
| RCT | EG+BFR | Stage 2 CKD; Patients in both groups displayed metabolic syndrome | 10 F and 25 M; 12 F and 23 M | 58.06; 58.09 | RT | Exercises: bench press, seated row, shoulder press, triceps pulley, barbell curls, leg press 45°, leg extension, and leg curl; first 2 months with 1–3 sets of 12 reps at 30% of 1-RM; Next 2 months with 2–3 sets of 10 reps at 40% of 1-RM; Last 2 months, 3 sets of 8 reps at 50% of 1-RM | 3 | 6 Months | 50% of LOP | ↓ Decelerate the decline in eGFR for both groups; ↓ Blood glucose, HbAlc and GTT; ↓ HOMA-IR for both groups; ↑ Irisin for both groups; ↔ Adiponectin for EG; ↑ Adiponectin for EG+BFR; ↑ SIRT-1 for both groups; ↓ Leptin for both groups; ↓ Insulin for both groups; ↓ C-reactive protein for both groups; ↓ Triglycerides for both groups | NR | |
RCT, randomized clinical trial; CD, crossover design; EG, experimental group without BFR; EG+BFR, experimental group with BFR; ESRD, end-stage renal disease; BFR, blood flow restriction; CKD, chronic kidney disease; HTN, hypertensive; CVD, cardiovascular disease; Reps, repetitions; RI, rest interval; RM, repetitions maximum; Min, minutes; HR, heart rate; AE, aerobic training; RT, resistance training; NR, not reported; F, female; M, male; HD, hemodialysis; UF, ultrafiltration rate; eKt/V, equilibrated Kt/V-urea; spKt/V, single-poll Kt/V-urea; RPE, rate of perceived exertion; eGFR, estimated glomerular filtration rate; LOP, limb occlusion pressure; TNF-α, tumor necrosis factor-alpha; IL-18, interleukin-18; FGF23, fibroblast growth factor 23; IL-10, interleukin-10; IL-15, interleukin-15; ADMA, asymmetric dimethylarginine; Ang 1-17, angiotensin 1-17; NO2-, nitric oxide; MPO, myeloperoxidase; PON1, paraoxonase 1; Δ, delta; RR, R–R intervals; SDNN, standard deviation of N–N interval time series; RMSSD, root mean square of successive differences in the N–N intervals; VLF, very low frequency; HbAlc, glycated hemoglobin; GTT, glucose tolerance test; ↓, significant decrease in the mean value (P<0.05); ↔, no significant change in the mean value (P> 0.05); ↑, significant increase in the mean value (P<0.05).
Proposed contraindications before exercise training with blood flow restriction exercise for chronic kidney disease patients
| Hemodynamic instability during hemodialysis over the last month (blood pressure of 180/105 mmHg systolic/diastolic, respectively during hemodialysis) |
| Pre-exercise blood pressure above 160/100 mmHg for systolic/diastolic, respectively before exercise |
| Neurodegenerative diseases |
| Autoimmune diseases (i.e., lupus erythematosus) |
| Human immunodeficiency |
| Symptomatic heart failure |
| History of nephrolithiasis |
| Coagulation or presence of signs of thrombophlebitis |
| Clinical acute coronavirus 2019 disease or other virus infection |
| Surgery within the past 3 months |
| Drug or alcohol abuse |
| Previous diagnosis of coronary artery disease or signs of symptomatic cardiovascular or peripheral vascular disease |
| Severe arrhythmia, angina or cerebrovascular disease |
| D-dimer values not in the normal range (220–500 ng/mL) |
| Admission to an intensive care unit |
| Previous surgery or vascular access in the upper limbs |
| Gains above >4 kg of weight since their last dialysis appointment/exercise session |
| Unstable on dialysis |
| Frequently changing medication regimen |
| Pulmonary congestion or peripheral edema |
Adapted from previous studies (Barbosa et al., 2018; Cardoso et al., 2020; Clarkson et al., 2020; Corrêa et al., 2021a; Corrêa et al., 2021b; de Deus et al., 2021; Deus et al., 2022; Dias et al., 2020; Gupta et al., 2020; Silva et al., 2021; Smart et al., 2013).
Considerations for blood flow restriction exercise in chronic kidney disease patients
| Programming variables to consider | Recommendation | Notes |
|---|---|---|
| Resistance training | First 2 months with 1–3 sets of 12 reps at 30% of 1-RM; Next 2 months with 2–3 sets of 10 reps at 40% of 1-RM; Last 2 months, 3 sets of 8 reps at 50% of 1-RM | Six months of a periodized all body RT displayed to be a proper method to increase muscle strength, regulate inflammation, glucose homeostasis, decelerate the decline in glomerular filtration rate, attenuate renal deterioration, control blood pressure, autonomic function, and antioxidant defense for stage 2 CKD. |
| Aerobic training | Cycling exercise, 20 min during the first 2 hr of HD. During the 3 first weeks use 60%–63% of maximal HR and 10–11 of RPE, progressing to 64%–76% of maximal HR and 12–13 of RPE. | Kidney health professional should use the following criteria to interrupt BFR training for ESRD patients during HD:
Exceeding 80% of the maximal HR and/or blood pressure above 200/110 mmHg or below 110/50 mmHg. Chest pain, dyspnea, wheezing, muscle cramps, mental confusion, visual disturbances, skin pallor or cyanosis. |
| % LOP | Arms: 50% | BFR training with 50% of LOP was effective as exercise alone in improving hemodialysis adequacy, comfort, and adherence. Thus, use of a validated doppler vascular device is necessary. |
| Frequency | 2 to 3 x/week | All patients should exercise under the individualized supervision of kidney health professionals. |
RM, repetition maximum; RT, resistance training; HD, hemodialysis; HR, heart rate; RPE, rate of perceived exertion; CKD, chronic kidney disease; ESRD, end-stage renal disease; LOP, limb occlusion pressure; BFR, blood flow restriction.
Based on previous studies (Barbosa et al., 2018; Cardoso et al., 2020; Clarkson et al., 2020; Corrêa et al., 2021a; Corrêa et al., 2021b; de Deus et al., 2021; Deus et al., 2022; Dias et al., 2020; Silva et al., 2021; Smart et al., 2013).
Fig. 1Impact of BFR exercise on health-related outcomes in patients with CKD. The figure was created in the Mind the Graph platform (www.mindthegraph.com). BFR, blood flow restriction; CKD, chronic kidney disease. Adapted from previous studies (Barbosa et al., 2018; Cardoso et al., 2020; Clarkson et al., 2020; Corrêa et al., 2021a; Corrêa et al., 2021b; de Deus et al., 2021; Deus et al., 2022; Dias et al., 2020; Silva et al., 2021).